Medical Hypotheses
Volume 57, Issue 2 , Pages 167-168, August 2001

Non-steroidal anti-inflammatory drugs in chemoprevention of breast and prostate cancer

  • A.F. Badawi

      Affiliations

    • Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA
  • ,
  • A. El-Sohemy

      Affiliations

    • Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada

Received 5 October 2000; accepted 17 January 2001.

Abstract 

Despite convincing evidence from animal experiments, epidemiological studies linking the use of non-steroidal anti-inflammatory drugs (NSAIDs) with lower risk of breast and prostate cancer have been equivocal. One explanation for the inconsistencies among epidemiological studies may relate to individual differences in NSAID metabolism due to genetic polymorphisms in enzymes such as N -acetyltransferases and cytochrome P4502C9, which are known to be involved in the metabolic biotransformation of NSAIDs. The exclusion of these molecular biomarkers of individual susceptibility may have contributed to the inconsistent findings on the effects of NSAIDs in breast and prostate cancer.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0306-9877(01)91332-5

doi:10.1054/mehy.2001.1332

Medical Hypotheses
Volume 57, Issue 2 , Pages 167-168, August 2001